Brought to you by 
DiObex closes $24mm Series B round
18 Apr 2007
Executive Summary
DiObex (therapeutics for metabolic disorders) raised $24mm in its Series B financing round led by Inventages Venture Capital with additional participation from new investors Mitsui Ventures and Pac-Link BioVentures, and returning shareholders Domain Associates, Pequot Ventures, and Sofinnova Ventures. The proceeds will be used to move the company's two lead compounds--DIO901 for Type I diabetes and DIO902 for Type II diabetes--through Phase II. A member each from Inventages, Mitsui, Sofinnova (chairman), and Pac-Link (observer) will join DiObex's board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DiObex closes $24mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice